Durvalumab and Tremelimumab for Pediatric Malignancies
Durvalumab and Tremelimumab for Pediatric Malignancies
Active, not recruiting · NCT03837899 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab and Tremelimumab for Pediatric Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, childhood malignant neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT03837899 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||